Biotech | February 27, 2022
HitGen completes research collaboration with MTPC
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Subscribe To Our Newsletter & Stay Updated
